News & Updates

Show Multimedia Only

Original New Drug Application Approvals by US FDA (01 - 15 June 2022)

15 Jun 2022

New drug applications approved by US FDA as of 01 - 15 June 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01 - 15 June 2022)

15 Jun 2022

Venetoclax boosts HRQoL in AML patients unfit for intensive chemotherapy

14 Jun 2022

Drug combinations including venetoclax seem to have a positive impact on health-related quality of life (HRQoL), or at least does not worsen it, in patients with acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy, a recent study has found.

Venetoclax boosts HRQoL in AML patients unfit for intensive chemotherapy

14 Jun 2022

Beta-blocker use reduces daily physical activity

14 Jun 2022

Treatment with beta-blockers in hypertension may decrease daily physical activity but not maximal exercise performance, a study has found.

Beta-blocker use reduces daily physical activity

14 Jun 2022

Amiodarone use may reduce survival in continuous‐flow left ventricular assist device recipients

14 Jun 2022

For patients who have undergone continuous‐flow left ventricular assist device (CF‐LVAD) implantation, treatment with amiodarone may do more harm than good, with a recent study showing that it contributes to increased risk of mortality.

Amiodarone use may reduce survival in continuous‐flow left ventricular assist device recipients

14 Jun 2022

Prophylactic 5-FU plus heparin not effective against proliferative vitreoretinopathy in RRD

14 Jun 2022

Adjuvant therapy with 5-fluorouracil (5-FU) and low molecular weight heparin in high-risk patients with rhegmatogenous retinal detachment (RRD) does not help prevent the development of proliferative vitreoretinopathy, as shown in a study.

Prophylactic 5-FU plus heparin not effective against proliferative vitreoretinopathy in RRD

14 Jun 2022

Infection + vaccination = The best protection against COVID-19?

13 Jun 2022 by

Individuals with a prior COVID-19 infection and who are fully vaccinated against COVID-19 appear to have the greatest immunity to the virus, according to the SIREN* study.

Infection + vaccination = The best protection against COVID-19?

13 Jun 2022

Haemodialysis delivers urate-lowering benefit to patients with gout, ESRD

12 Jun 2022

In patients with gout and end-stage renal disease (ESRD), haemodialysis appears to have an additional benefit of lowering uric acid (UA) levels, a study has found.

Haemodialysis delivers urate-lowering benefit to patients with gout, ESRD

12 Jun 2022

Pranlukast cuts need for respiratory support in infants with RSV

12 Jun 2022

The use of pranlukast in infants with respiratory syncytial virus (RSV) infections appears to help avoid the need for respiratory support, a recent Japan study has found.

Pranlukast cuts need for respiratory support in infants with RSV

12 Jun 2022

Azithromycin improves asthma control, cuts exacerbations in children

11 Jun 2022

In the treatment of children with poorly controlled asthma, the use of azithromycin helps improve asthma control and reduce exacerbations, according to a study.

Azithromycin improves asthma control, cuts exacerbations in children

11 Jun 2022

Paclitaxel-coated devices in femoropopliteal artery revascularization: Mortality risk fears unfounded?

10 Jun 2022 by

Among patients undergoing femoropopliteal artery revascularization, mortality risk was not affected regardless of whether they were treated with drug-coated devices (DCDs) or non–drug-coated devices (NDCDs), according to updated results of the SAFE-PAD* study presented at SCAI 2022.

Paclitaxel-coated devices in femoropopliteal artery revascularization: Mortality risk fears unfounded?

10 Jun 2022

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Original New Drug Application Approvals by US FDA (01 - 15 June 2022)

Original New Drug Application Approvals by US FDA (01 - 15 June 2022)

Venetoclax boosts HRQoL in AML patients unfit for intensive chemotherapy

Venetoclax boosts HRQoL in AML patients unfit for intensive chemotherapy

Beta-blocker use reduces daily physical activity

Beta-blocker use reduces daily physical activity

Amiodarone use may reduce survival in continuous‐flow left ventricular assist device recipients

Amiodarone use may reduce survival in continuous‐flow left ventricular assist device recipients

Prophylactic 5-FU plus heparin not effective against proliferative vitreoretinopathy in RRD

Prophylactic 5-FU plus heparin not effective against proliferative vitreoretinopathy in RRD

Infection + vaccination = The best protection against COVID-19?

Infection + vaccination = The best protection against COVID-19?

Haemodialysis delivers urate-lowering benefit to patients with gout, ESRD

Haemodialysis delivers urate-lowering benefit to patients with gout, ESRD

Pranlukast cuts need for respiratory support in infants with RSV

Pranlukast cuts need for respiratory support in infants with RSV

Azithromycin improves asthma control, cuts exacerbations in children

Azithromycin improves asthma control, cuts exacerbations in children

Paclitaxel-coated devices in femoropopliteal artery revascularization: Mortality risk fears unfounded?

Paclitaxel-coated devices in femoropopliteal artery revascularization: Mortality risk fears unfounded?